TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04796779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology Pro
Description: The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology V1.5
Description: The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem t:slim X2 with Control-IQ Technology V1.5
Description: The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features.
Study: NCT05162365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314
Description: Low/medium/high dose, intravenously, once, on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, intravenously, once, on Day 1
Study: NCT05414032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
Study: NCT00666783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
Study: NCT05529251

Intervention type: DRUG
Group type: OTHER
Intervention: 3 cycles of EP
Description: 3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
Study: NCT05003908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT04874584

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Chemotherapy Education
Description: Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
Study: NCT05636059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + cryotherapy
Description: Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
Study: NCT05690971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
Study: NCT06507085

Intervention type: RADIATION
Intervention: Radio-guided interventions to correct heart rhythm disorders
Description: All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate
Study: NCT05456412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JAK inhibitor treatment
Description: Standard care
Study: NCT05679609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
Study: NCT06526806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot game strategy
Description: Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course.
Study: NCT06187311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG
Description: Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Study: NCT05588180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FVD/FAD ratio guided
Description: Ultrasound-guided ratio

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV
Description: PPV
Study: NCT05957588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proning group
Description: Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
Study: NCT04994080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol QD Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD or TIW
Study: NCT06303349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samples collection
Description: from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it.
Study: NCT05386264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded autologous T regulatory cells
Description: A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
Study: NCT04813276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Together serious game
Description: The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
Study: NCT05734664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsify sensor
Description: A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: State-of-the-art ultrasound equipment
Description: A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
Study: NCT04813276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual
Description: A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
Study: NCT06207695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Group Intervention
Description: This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
Study: NCT06313853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH-Cog
Description: Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
Study: NCT05249712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 300 mg
Description: 600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
Study: NCT05950971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone, diltiazem or esmolol
Description: Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone, diltiazem or esmolol
Description: Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
Study: NCT05544227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-102
Description: SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
Study: NCT05386927

Intervention type: OTHER
Intervention: Questionnaire survey and specimen collection
Description: A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.

Intervention type: OTHER
Intervention: Questionnaire survey and specimen collection
Description: A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
Study: NCT06403748

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.
Description: The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04871230

Intervention type: DIAGNOSTIC_TEST
Intervention: 3G DBS
Description: Collection of capillary blood samples for the 3G q-PCR test

Intervention type: DIAGNOSTIC_TEST
Intervention: 3G DBS
Description: Collection of capillary blood samples for the 3G q-PCR test

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum Test
Description: Collection of sputum for test culture, microscopy, GeneXpert

Intervention type: DIAGNOSTIC_TEST
Intervention: 3G Veinous Blood
Description: Collection liquid veinous blood for the 3G q-PCR test

Intervention type: DIAGNOSTIC_TEST
Intervention: 3G Veinous Blood
Description: Collection liquid veinous blood for the 3G q-PCR test
Study: NCT05579119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100 mg po once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Glargine once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
Study: NCT05226897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC405-T
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YYC405-T placebo
Description: Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Study: NCT05892263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early feeding
Description: Enteral force feeding with 5% dextrose injection within 24 hours after operation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early feeding
Description: Enteral force feeding with 5% dextrose injection within 24 hours after operation
Study: NCT05636059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + joint mobilization
Description: Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
Study: NCT04656392

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath test (eNose) followed by uTNE.
Description: All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
Study: NCT05838209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: test
Description: Ozone oil used as an adjunctive of scaling and root planing and control,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: saline solution 0.09% used as an adjunctive as scaling and root planing
Study: NCT06411223

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative drug therapy management model
Description: CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Cabotegravir/Rilpivirine
Description: Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
Study: NCT06119451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Music Therapy
Description: Intervention using traditional music therapy as an alternative therapy for burnout syndrome
Study: NCT05439018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular inhibition
Description: Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
Study: NCT05145712

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bowel readiness
Description: During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year